Literature DB >> 230783

Growth inhibition by acycloguanosine of herpesviruses isolated from human infections.

C S Crumpacker, L E Schnipper, J A Zaia, M J Levin.   

Abstract

Inhibition by acycloguanosine (ACG) of plaque formation by harpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella-zoster virus, and cytomegalovirus was studied. Seventeen clinical isolates of HSV-1 were inhibited by ACG at a mean 50% inhibitory dose (ID(50)) of 0.15 +/- 0.09 muM. The mean ID(50) for 10 isolates of HSV-2 was 1.62 +/- 0.76 muM, and for four isolates of varicella-zoster virus it was 3.75 +/- 1.30 muM. The ID(50)'s for two cytomegalovirus isolates were 100 and 160 muM, and for four additional isolates of cytomegalovirus no end point (ID(50)) was reached at 200 muM. ACG at a concentration of 200 muM had no effect on deoxyribonucleic acid synthesis in human fibroblast cells and only inhibited thymidine incorporation by Vero cells by one-third. These studies demonstrated the antiviral activity of ACG against clinical isolates of HSV-1, HSV-2, and varicella-zoster virus and the lack of toxicity to monkey or human cells in culture at concentrations which markedly inhibited these viruses. ACG had little effect on cytomegalovirus at concentrations in excess of 100 muM.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 230783      PMCID: PMC352730          DOI: 10.1128/AAC.15.5.642

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Delayed-type hypersensitivity to sheep red blood cells: inhibition of sensitization by interferon.

Authors:  J De Maeyer-Guignard; A Cachard; E De Maeyer
Journal:  Science       Date:  1975-11-07       Impact factor: 47.728

2.  NIH conference. Herpes zoster-varicella infections in immunosuppressed patients.

Authors:  R Dolin; R C Reichman; M H Mazur; R J Whitley
Journal:  Ann Intern Med       Date:  1978-09       Impact factor: 25.391

3.  Genital Herpesvirus homonis infection in mice. II. Treatment with phosphonoacetic acid, adenine arabinoside, and adenine arabinoside 5'-monophosphate.

Authors:  E R Kern; J T Richards; J C Overall; L A Glasgow
Journal:  J Infect Dis       Date:  1977-04       Impact factor: 5.226

4.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

5.  5,6-Dihydro-5-azathymidine: in vitro antiviral properties against human herpesviruses.

Authors:  H E Renis
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

6.  9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.

Authors:  H J Schaeffer; L Beauchamp; P de Miranda; G B Elion; D J Bauer; P Collins
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

7.  The natural history of recurrent facial-oral infection with herpes simplex virus.

Authors:  C Bader; C S Crumpacker; L E Schnipper; B Ransil; J E Clark; K Arndt; I M Freedberg
Journal:  J Infect Dis       Date:  1978-12       Impact factor: 5.226

8.  Neutropenia and thrombocytopenia after repeated courses of leucocyte interferon.

Authors:  S J Urbaniak; I M Halliday; G W Beveridge; A V Kay
Journal:  Lancet       Date:  1978-03-11       Impact factor: 79.321

9.  Varicella in children with cancer: Seventy-seven cases.

Authors:  S Feldman; W T Hughes; C B Daniel
Journal:  Pediatrics       Date:  1975-09       Impact factor: 7.124

10.  Antiviral activity of arabinosylthymine in herpesviral replication: mechanism of action in vivo and in vitro.

Authors:  J F Aswell; G P Allen; A T Jamieson; D E Campbell; G A Gentry
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

View more
  69 in total

1.  Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir.

Authors:  D M Coen; D J Goldstein; S K Weller
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

2.  Clear detection and typing of herpes simplex virus types 1 and 2 by an indirect ELISA assay: comparison with three different combined methods--capture ELISA, restriction enzymes, and polymerase chain reaction.

Authors:  P Markoulatos; P Fountoucidou; G Marinakis; V Krikelis; N Spyrou; N Vamvakopoulos; M L Moncany
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

3.  Treatment of experimental cytomegalovirus infections with acyclovir.

Authors:  C A Bruggeman; W Engels; J Endert
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

Review 4.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

5.  A comparative study of the polymerase chain reaction and local antibody production in acute retinal necrosis syndrome and cytomegalovirus retinitis.

Authors:  T Abe; K Tsuchida; M Tamai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-07       Impact factor: 3.117

6.  Selective anabolism of 6-methoxypurine arabinoside in varicella-zoster virus-infected cells.

Authors:  K K Biron; P de Miranda; T C Burnette; T A Krenitsky
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

7.  Topical Acyclovir for Recurrent Herpes Labialis in Primary Care: Critical appraisal.

Authors:  G Worrall
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

Review 8.  Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogues. A review.

Authors:  T Kulikowski
Journal:  Pharm World Sci       Date:  1994-04-15

Review 9.  Antiherpes drugs: promises and pitfalls.

Authors:  E de Clercq
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

10.  Resistance of herpes simplex virus to 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine: physical mapping of drug synergism within the viral DNA polymerase locus.

Authors:  C S Crumpacker; P N Kowalsky; S A Oliver; L E Schnipper; A K Field
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.